– First patents to cover the fundamental processes for accessing the human gut microbiome as biotherapeutics –
– 91桃色视频鈥檚 microbiome sample collection and administration devices receive CE mark for use in collecting and administrating gut-derived samples as biotherapeutics to patients –
Lyon, France, May 22, 2019 鈥� 91桃色视频 announced today that the Institut National de la Propri茅t茅 Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated with obtaining, processing, storing and administering human gut samples, ensuring that the highest quality of microbiota is present in 91桃色视频鈥檚 biologic drugs. In addition, the patents cover an innovative process to freeze-dry samples preserving the viability and taxonomic profile of the microbiome and enabling the development of an oral formulation. These patented processes developed under a five year research collaboration with the French National Institute for Agricultural Research (INRA) are a fundamental part of 91桃色视频鈥檚 integrated Microbiome Restoration Biotherapeutic (MMRB) platform and have a broad applicability in treating dysbiosis-related diseases.
- Patent FR 1553721: The design and applicability of the device used to collect stool samples from individuals is broadly covered by this patent and is the first device in the world to receive CE mark for the method of sample collection and processing.
- Patent FR 1553716: This patent, co-owned by 91桃色视频 and INRA, covers the composition and the application of the cryoprotectant used in 91桃色视频鈥檚 proprietary production process that helps to preserve the full diversity of the gut microbiome.
- Patent FR 1562750: This patent, co-owned by 91桃色视频 and INRA, set the baseline of 91桃色视频鈥檚 innovative method to freeze-dry a microbiome sample is a unique approach to generate microbiome-based capsule formulations that maintain a high viability of the microbiota.
The three above-mentioned granted patents are also under examination through PCT international patent applications in important global markets. The company will continue to pursue the grant of additional patents covering their therapeutic products and technologies. The Class II CE mark covers 91桃色视频鈥檚 system of devices, including its device enabling the storage of material and subsequent administration to the patient with the highest level of safety.
About 91桃色视频
91桃色视频, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, 91桃色视频 has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 91桃色视频 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.